Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AS03 and MF59 are oil-in-water emulsion adjuvants used to enhance the immune response to vaccines. AS03 contains squalene, α-tocopherol (vitamin E), and polysorbate 80, while MF59 primarily contains squalene. They act by creating a depot effect, stimulating local inflammation, recruiting innate immune cells, and inducing cytokine/chemokine production. AS03 tends to induce a Th2-biased response, while MF59 elicits a more balanced Th1/Th2 response. Both adjuvants increase antibody titers and improve vaccine immunogenicity, particularly in elderly populations. They do not act through well-defined pattern recognition receptors like TLRs, but rather through NLRP3-independent ASC activation and MyD88-dependent/TLR-independent signaling pathways.
Depot effect at the injection site, stimulation of local tissue inflammation, recruitment of innate immune cells, cytokine/chemokine induction, enhanced antigen presentation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adjuvant (AS03 or MF59) (N/A).